|
CA3139033A1
(en)
|
2012-08-22 |
2014-02-27 |
Cornell University |
Methods for inhibiting fascin
|
|
PL3023415T3
(pl)
|
2012-10-02 |
2018-06-29 |
Gilead Sciences, Inc. |
Inhibitory demetylaz histonowych
|
|
SMT201800070T1
(it)
|
2012-12-19 |
2018-03-08 |
Celgene Quanticel Res Inc |
Inibiorti di istone demetilasi
|
|
PE20151417A1
(es)
|
2012-12-21 |
2015-10-10 |
Quanticel Pharmaceuticals Inc |
Inhibidores de histona desmetilasa
|
|
BR112015020650A2
(pt)
|
2013-02-27 |
2017-07-18 |
Epitherapeutics Aps |
inibidores de histona demetilases
|
|
CA2903473A1
(en)
|
2013-03-12 |
2014-10-09 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
|
BR112015022545A2
(pt)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
compostos de pirazolo e os usos disso
|
|
CA3195815A1
(en)
|
2014-02-20 |
2015-08-27 |
Cornell University |
Compounds and methods for inhibiting fascin
|
|
WO2015200709A1
(en)
|
2014-06-25 |
2015-12-30 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
|
BR112017003442A2
(pt)
|
2014-08-27 |
2017-11-28 |
Gilead Sciences Inc |
compostos e métodos para inibir histona desmetilases
|
|
SG11201702147TA
(en)
|
2014-09-17 |
2017-04-27 |
Celgene Quanticel Res Inc |
Histone demethylase inhibitors
|
|
AU2015318111A1
(en)
|
2014-09-17 |
2017-04-13 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
US10030017B2
(en)
|
2014-09-17 |
2018-07-24 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
JP6883913B2
(ja)
*
|
2015-12-28 |
2021-06-09 |
セルジーン クオンティセル リサーチ，インク． |
ヒストンデメチラーゼ阻害剤
|
|
CN105601555B
(zh)
*
|
2016-03-14 |
2018-07-31 |
苏州大学 |
一种制备硝基吲哚衍生物的方法
|
|
JP6970681B2
(ja)
*
|
2016-03-15 |
2021-11-24 |
セルジーン クオンティセル リサーチ，インク． |
ヒストンデメチラーゼ阻害剤
|
|
US10150754B2
(en)
|
2016-04-19 |
2018-12-11 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
KR102202984B1
(ko)
|
2016-05-27 |
2021-01-13 |
길리애드 사이언시즈, 인코포레이티드 |
Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
AU2017318601B2
(en)
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
|
IL265921B2
(en)
|
2016-10-14 |
2024-05-01 |
Prec Biosciences Inc |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
|
EP3535242B1
(en)
*
|
2016-10-20 |
2024-01-24 |
B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University |
Dna primase and gyrase inhibitors
|
|
TWI714820B
(zh)
|
2017-01-31 |
2021-01-01 |
美商基利科學股份有限公司 |
替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
WO2018149986A1
(en)
*
|
2017-02-16 |
2018-08-23 |
Oryzon Genomics, S.A. |
2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
|
|
EP3600301B1
(en)
|
2017-03-30 |
2024-07-03 |
Albert-Ludwigs-Universität Freiburg |
Kdm4 inhibitors
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
KR102492115B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
BR112020016466A2
(pt)
|
2018-02-13 |
2020-12-15 |
Gilead Sciences, Inc. |
Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1, para tratar câncer e para aprimorar a função de células-t em pacientes com hepatite b crônica (chb), e, kit para tratar ou prevenir câncer ou uma doença ou condição.
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
ES3035911T3
(en)
|
2018-04-19 |
2025-09-11 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
AU2019301811B2
(en)
|
2018-07-13 |
2022-05-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
JP7158577B2
(ja)
|
2018-10-24 |
2022-10-21 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
EP3873608A1
(en)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
AU2019372046B2
(en)
|
2018-10-31 |
2022-05-26 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
JP7350872B2
(ja)
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
３’３’－環状ジヌクレオチドおよびそのプロドラッグ
|
|
US12318403B2
(en)
|
2019-03-07 |
2025-06-03 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′-cyclic dinucleotides and prodrugs thereof
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
KR20220074917A
(ko)
|
2019-09-30 |
2022-06-03 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 백신 및 hbv를 치료하는 방법
|
|
CN116057068A
(zh)
|
2019-12-06 |
2023-05-02 |
精密生物科学公司 |
对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
|
|
AU2021237718B2
(en)
|
2020-03-20 |
2023-09-21 |
Gilead Sciences, Inc. |
Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
PE20230779A1
(es)
|
2020-08-07 |
2023-05-09 |
Gilead Sciences Inc |
Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
JP2024518558A
(ja)
|
2021-05-13 |
2024-05-01 |
ギリアード サイエンシーズ， インコーポレイテッド |
ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ
|
|
CA3220923A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117377671A
(zh)
|
2021-06-23 |
2024-01-09 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
KR20250109234A
(ko)
|
2022-11-21 |
2025-07-16 |
니뽄 신야쿠 가부시키가이샤 |
Ddr1 키나아제 저해제로서의 화합물 및 의약
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|